NRX Pharmaceuticals Income Statement (2017-2026) | NRXP

Income Statement Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.20M0.96M1.07M
Cost of Revenue (Quarter)
0.10M0.41M0.63M
Gross Profit (Quarter)
0.10M0.55M0.44M
Operating items
Research & Development (Quarter)
4.66M6.28M6.41M5.48M2.96M4.13M4.46M0.80M3.87M3.31M2.53M1.75M2.80M0.61M1.04M0.80M0.99M1.43M0.56M1.31M
Selling, General & Administrative (Quarter)
2.30M13.82M46.56M10.22M6.64M5.01M5.43M2.94M4.07M2.49M1.87M4.25M4.25M2.41M2.60M2.94M2.74M2.81M4.57M3.81M
Restructuring Costs (Quarter)
0.10M0.25M-1.20M0.10M-0.09M0.03M-0.01M
Other Operating Expenses (Quarter)
10.16M0.00M0.00M0.12M0.45M0.69M
Operating Expenses (Quarter)
17.12M20.10M52.98M15.71M9.60M9.14M9.89M3.85M8.19M5.81M4.41M6.00M7.05M3.02M2.43M3.85M3.73M4.27M5.61M5.81M
Operating Income (Quarter)
-17.12M-20.10M-52.98M-15.71M-9.60M-9.14M-9.89M-3.85M-8.19M-5.81M-4.41M-6.00M-7.05M-3.02M-2.43M-3.85M-3.73M-4.02M-4.62M-4.74M
EBIT (Quarter)
-17.12M-20.10M-52.98M-15.71M-9.60M-9.14M-9.89M-3.85M-8.19M-5.81M-4.41M-6.00M-7.05M-3.02M-2.43M-3.85M-3.73M-4.02M-4.62M-4.74M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)
0.02M0.10M0.13M0.00M0.14M0.12M0.07M0.03M0.01M0.01M0.00M0.00M0.00M0.00M0.00M0.01M
Other Non Operating Income (Quarter)
17.36M-16.54M1.57M0.16M0.12M-0.04M0.02M0.01M-0.01M0.03M-0.01M-0.01M
Non Operating Income (Quarter)
17.00M-16.95M22.57M2.26M2.62M0.06M-0.35M-1.67M-0.53M-0.25M0.07M-0.53M-0.85M1.40M-6.65M-1.67M-13.85M-1.87M4.98M3.31M
Net income details
EBT (Quarter)
-0.12M-37.05M-30.41M-16.71M-9.75M-9.32M-12.31M-3.97M-8.09M-6.19M-4.41M-6.34M-7.04M-3.02M-2.43M-3.84M-3.73M-4.21M-4.62M-4.97M
Tax Provisions (Quarter)
0.00M
Profit After Tax (Quarter)
-0.12M-37.05M-30.41M-13.45M-6.98M-9.08M-10.24M-5.51M-8.72M-6.06M-4.31M-6.53M-7.90M-1.62M-9.07M-5.51M-17.58M-5.89M0.40M-1.40M
Income from Continuing Operations (Quarter)
-0.12M-37.05M-30.41M-16.71M-9.75M-9.32M-12.31M-3.97M-8.09M-6.19M-4.41M-6.34M-7.04M-3.02M-2.43M-3.84M-3.73M-4.21M-4.62M-4.97M
Consolidated Net Income (Quarter)
-0.12M-37.05M-30.41M-16.71M-9.75M-9.32M-12.31M-3.97M-8.09M-6.19M-4.41M-6.34M-7.04M-3.02M-2.43M-3.84M-3.73M-4.21M-4.62M-4.97M
Income towards Parent Company (Quarter)
-17.48M-37.05M-30.41M-16.71M-9.75M-9.32M-12.31M-3.97M-8.09M-6.19M-4.41M-6.34M-7.04M-3.02M-2.43M-3.84M-3.73M-4.21M-4.62M-4.97M
Preferred Dividend Payments (Quarter)
0.01M
Net Income towards Common Stockholders (Quarter)
-255.94M-37.05M-30.41M-16.71M-6.98M-9.08M-10.24M-3.97M-8.09M-6.19M-4.41M-6.34M-7.04M-3.02M-2.43M-3.84M-3.73M-4.21M-4.62M-4.97M
Additional items
EPS (Basic) (Quarter)
-61.34-7.16-6.48-2.62-1.06-1.37-1.56-0.59-1.10-0.76-0.58-0.72-0.67-0.28-0.23-0.23-0.21-0.19-0.22-0.15
EPS (Diluted) (Quarter)
-61.34-7.26-6.48-2.62-1.06-1.37-1.56-0.59-1.10-0.76-0.54-0.72-0.80-0.34-0.27-0.43-0.42-0.48-0.52-0.56
Shares Outstanding (Quarter)
4.17M5.17M4.69M6.37M6.57M6.64M6.58M6.75M7.32M8.19M7.58M8.85M10.52M10.97M10.64M16.41M17.93M22.23M21.40M32.33M
Shares Outstanding (Diluted) (Quarter)
4.17M5.11M4.69M6.37M6.57M6.64M6.58M6.75M7.32M8.19M8.19M8.85M8.85M8.85M8.85M8.85M8.85M8.85M8.85M8.85M
Shares Outstanding (Entity) (Quarter)
4.86M5.48M4.69M6.66M6.66M6.76M6.64M7.03M8.04M8.39M8.39M9.77M10.79M11.37M10.64M17.12M19.47M22.23M21.40M33.47M
EBITDA (Quarter)
-17.12M-20.10M-52.98M-15.71M-9.60M-9.14M-9.89M-3.85M-8.19M-5.81M-4.41M-6.00M-7.05M-3.02M-2.43M-3.85M-3.73M-4.02M-4.62M-4.74M
Interest Expenses (Quarter)
20.56M12.45M0.00M1.01M0.17M0.28M2.55M0.12M0.05M0.50M0.08M0.37M0.19M0.23M
Tax Rate (Quarter)
-0.10%